Asian CRO gains $22M in second round

The Asian CRO Bridge Pharmaceuticals has raised $22 million in its second round. Bridge is a spin-off of SRI International and operates a preclinical laboratory in Beijing. Much of the new funds came from returning first round investors. The new money will be used to develop its business and fund new acquisitions.

- here's the release on the Bridge round

PLUS: BioProcessors has won $18 million in a third round of venture capital. HLM Venture Partners led the round for the Woburn, MA-based company. BioProcessors provides micro-engineered solutions for biopharmaceutical process development applications for the biopharma industry. "We have been long impressed with BioProcessors' solutions, which have a proven track record of exponentially increasing experimental efficiency and scaling-up candidate drug production," said Russ Ray, a managing partner at HLM Venture Partners. Release

ALSO: Danube Pharmaceuticals has raised $10 million in its first round. Much of that money will go to develop its lead compound for glaucoma. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.